Gavin James R
Healing Our Village, Inc, Lanham, Maryland, USA.
J Am Osteopath Assoc. 2012 Jan;112(1 Suppl 1):S16-21.
Control of blood glucose levels and restoration of pancreatic islet function are among the goals of physicians seeking to improve outcomes in patients with type 2 diabetes mellitus (T2DM). A growing body of evidence supports the use of incretins to achieve these goals, and current guidelines recommend earlier and more frequent use of these agents. However, in patients with T2DM, treatment paradigms should always be individualized. The author discusses issues for physicians to consider when adjusting T2DM therapy, including patient comorbidities, glucose control patterns, and potential adverse effects. The importance of patient education and practical points for initiating a glucagon-like peptide-1 receptor agonist are also reviewed.
控制血糖水平和恢复胰岛功能是寻求改善2型糖尿病（T2DM）患者治疗效果的医生的目标之一。越来越多的证据支持使用肠促胰岛素来实现这些目标，当前指南建议更早、更频繁地使用这些药物。然而，对于T2DM患者，治疗方案应始终个体化。作者讨论了医生在调整T2DM治疗时应考虑的问题，包括患者的合并症、血糖控制模式和潜在的不良反应。还回顾了患者教育的重要性以及启动胰高血糖素样肽-1受体激动剂的实用要点。
